29 October 2018 | News
The MGI proprietary technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flow cell, fluid, and biochemical and optical system.
MGI, a subsidiary of BGI Group, introduced its newest model of genetic sequencer, MGISEQ-T7, which vastly improves speed, throughput and flexibility, at the 13th International Conference on Genomics (ICG-13) in Shenzhen.
The most powerful MGI sequencer to date, MGISEQ-T7 is built with innovative quadruple flow-cell staging that allows simultaneous but independent operation of 1 to 4 flow cells in a single run.
The MGI proprietary technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flow cell, fluid, and biochemical and optical system. A supercomputer for the life science industry, MGISEQ-T7 takes the production capacity of the sequencer to a new level with the daily output of data up to 6Tb.
"Now customers have complete flexibility for a wide range of sequencing all in one machine," said MGI CEO Feng Mu.
"MGI is the first company that can achieve affordable and essentially error-free genome sequencing," said Dr. George Church, Professor of Genetics, and Health Sciences and Technology of Harvard and MIT.
The ultra-fast, ultra-high-throughput MGISEQ-T7 can complete WGS for up to 60 human genomes in a single day, breaking barriers for what a next-generation sequencer can do. MGISEQ-T7 accelerates the development of nationwide genomics projects since a T7 can complete the sequencing of 10,000 genomes within a year.
BGI Group President Jian Wang said such research will benefit human beings everywhere. "The mission of MGI is to help people live better and healthier lives."